Rimegepant's primary composition patent is set to expire in 2036. However, additional patents covering its formulation and methods of use could extend its market exclusivity further, potentially through 2040. DrugPatentWatch.com tracks these patent landscapes for various drugs. [1]
When does Rimegepant's main patent expire?
The foundational patent for rimegepant, a medication used to treat acute migraine, is scheduled to expire in 2036. [1]
Are there other patents protecting Rimegepant?
Beyond the primary composition patent, rimegepant is also protected by secondary patents. These patents address specific aspects such as its formulation and the methods by which it is administered or used for treating migraines. These secondary patents can influence the overall period of market protection. [1]
How long could Rimegepant remain under patent protection?
Considering the expiration of the primary patent in 2036 and the existence of secondary patents, rimegepant's market exclusivity could potentially extend until 2040. These later-expiring patents are often crucial for manufacturers seeking to prolong their market position. [1]
What is Rimegepant used for?
Rimegepant is prescribed for the acute treatment of migraine with or without aura in adults. [2]
What companies are involved with Rimegepant?
Biohaven Pharmaceuticals developed and markets rimegepant. Pfizer acquired Biohaven in 2022. [3]
How does Rimegepant work?
Rimegepant functions as a calcitonin gene-related peptide (CGRP) receptor antagonist. By blocking the action of CGRP, it helps to relieve migraine pain and associated symptoms. [2]
What is the difference between Rimegepant and other migraine treatments?
Rimegepant belongs to a class of drugs known as gepants, which target the CGRP pathway. This differs from older migraine treatments like triptans, which work on serotonin receptors. Gepants are considered an option for patients who cannot use or do not respond to triptans. [2]
What is the status of generic Rimegepant development?
The development of generic versions of rimegepant will be influenced by the expiration dates of its patents. Once patents expire, or if they are successfully challenged, generic manufacturers may be able to enter the market. DrugPatentWatch.com provides detailed patent expiration timelines for drugs like rimegepant. [1]
What are the potential risks associated with Rimegepant?
Common side effects of rimegepant can include nausea and fatigue. More serious, though less common, risks may be associated with its use, and patients should discuss these with their healthcare providers. [2]
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.rxlist.com/nurtec-odt-drug.htm
[3] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven